Screener
Syndax Pharmaceuticals SNDX Interest Income
Interest Income at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:InvestmentIncomeInterest.
The source filing: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-197154
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Other (expense) income, net: | ||
| Royalty interest expense | (11,846) | (8,049) |
| Other interest expense | — | (2) |
| Interest income | 3,561 | 7,183 |
| Other expense | (186) | (221) |
| Total other (expense) income, net | (8,471) | (1,089) |
| Net loss | $(42,673) | $(84,846) |
| Other Comprehensive loss: |
Item 1: Financial Statements
FAQ
- What is Syndax Pharmaceuticals's interest income?
- Syndax Pharmaceuticals (SNDX) reported interest income of $3.56M in Q1 2026.
- How has Syndax Pharmaceuticals's interest income changed year-over-year?
- Syndax Pharmaceuticals's interest income decreased by 50.4% year-over-year, from $7.18M to $3.56M.
- What is the long-term trend for Syndax Pharmaceuticals's interest income?
- Over 4 years (2021 to 2025), Syndax Pharmaceuticals's interest income has grown at a 174.2% compound annual growth rate (CAGR), from $402K to $22.73M.
- What does interest income mean?
- Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.
Ask your AI about Syndax Pharmaceuticals's interest income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude